Evaluation of alternative strategies to optimize ketorolac transdermal delivery

AAPS PharmSciTech

Volumn 7, Issue 3, 2006, Pages

  Puglia, Carmelo ^a   Filosa, Rosanna ^b   Peduto, Antonella ^b   de Caprariis, Paolo ^b   Rizza, Luisa ^a   Bonina, Francesco ^a   Blasi, Paolo ^c  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Ketorolac; Lipid carrier; NLC; Prodrug; Transdermal delivery

Indexed keywords

5 BENZOYL 2,3 DIHYDRO 1H PYRROLIZINE 1 CARBOXYLIC ACID DIETHYLENE GLYCOL ESTER; 5 BENZOYL 2,3 DIHYDRO 1H PYRROLIZINE 1 CARBOXYLIC ACID PENTAETHYLENE GLYCOL ESTER; 5 BENZOYL 2,3 DIHYDRO 1H PYRROLIZINE 1 CARBOXYLIC ACID TETRAETHYLENE GLYCOL ESTER; 5 BENZOYL 2,3 DIHYDRO 1H PYRROLIZINE 1 CARBOXYLIC ACID TRIETHYLENE GLYCOL ESTER; ESTER DERIVATIVE; GLYCEROL BEHENATE; KETOROLAC; MIGLYOL; NANOPARTICLE; PRODRUG; UNCLASSIFIED DRUG; DRUG CARRIER; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EPIDERMIS; ESTERIFICATION; GEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MATHEMATICAL COMPUTING; PARTICLE SIZE; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; SKIN ABSORPTION; SKIN PERMEABILITY; STRATUM CORNEUM; SUSTAINED DRUG RELEASE; CHEMISTRY; EVALUATION; FEMALE; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; KETOROLAC; PRODRUGS; SKIN ABSORPTION;

EID: 33747736644     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt070364     Document Type: Article

References (33)

1. Kokki H. Nonsteroidal anti-inflammatory drugs for postoperative pain: a focus on children. Paediatr Drugs. 2003;5:103-123.
2. Buckley MM, Brogden RN. Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990;39:86-109.
3. Reinhart DI. Minimizing the adverse effects of ketorolac. Drug Saf. 2000;22:487-497.
4. Parikh DK, Ghosh TK. Feasibility of transdermal delivery of fluoxetine. AAPS PharmSciTech. 2005;6:E144-E149.
5. Doh HJ, Cho WJ, Yong CS, et al. Synthesis and evaluation of ketorolac ester prodrugs for transdermal delivery. J Pharm Sci. 2003;92: 1008-1017.
6. Foldvari M. Non-invasive administration of drugs through the skin: challenges in delivery system design. Pharm Sci Technol Today. 2000; 3:417-425.
7. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14:101-114.
8. Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm. 2005;59:485-490.
9. Cho YA, Gwak HS. Transdermal delivery of ketorolac tromethamine: effects of vehicles and penetration enhancers. Drug Dev Ind Pharm. 2004;30:557-564.
10. Tiwari SB, Udupa N. Investigation into the potential of iontophoresis facilitated delivery of ketorolac. Int J Pharm. 2003;260:93-103.
11. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-177.
12. Kim BY, Doh HJ, Le TN, et al. Ketorolac amide prodrugs for transdermal delivery: stability and in vitro rat skin permeation studies. Int J Pharm. 2005;293:193-202.
13. Bonina FP, Montenegro L, de Caprariis P, Palagiano F, Trapani G, Liso G. In vitro and in vivo evaluation of polyoxyethylene indomethacin esters as dermal prodrugs. J Control Release. 1995;34:223-232.
14. Inagi T, Muramatsu T, Nagai H, Terada H. Mechanism of indomethacin partition between n-octanol and water. Chem Pharm Bull (Tokyo). 1981;29:2330-2337.
15. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparation of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Control Release. 1993;25:89-98.
16. Kligman AM, Christophers E. Preparation of isolated sheets of human stratum corneum. Arch Dermatol. 1963;88:702-705.
17. Swarbrick J, Lee G, Brom J. Drug permeation through human skin: I. Effect of storage conditions of skin. J Invest Dermatol. 1982;78: 63-66.
18. Bronaugh RL, Stewart RF, Simon M. Methods for in vitro percutaneous absorption studies VII: use of excised human skin. J Pharm Sci. 1986;75:1094-1097.
19. Touitou E, Fabin B. Altered skin permeation of a highly lipophilic molecule: tetrahydrocannabinol. Int J Pharm. 1988; 43:17-22.
20. Siewert M, Dressman J, Brown CK, Shah VP. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech. 2003;4:E7.
21. Bonina FP, Puglia C, Barbuzzi T, et al. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur J Pharm Sci. 2001;14:123-134.
22. Goldsmith LA. Physiology, Biochemistry, and Molecular Biology of the Skin. New York, NY: Oxford University Press; 1991.
23. Yalkowsky SH, Valvani SC. Solubility and partitioning I: solubility of nonelectrolytes in water. J Pharm Sci. 1980;69:912-922.
24. Yalkowsky SH, Valvani SC, Roseman TJ. Solubility and partitioning VI: octanol solubility and octanol-water partition coefficients. J Pharm Sci. 1983;72:866-870.
25. Osborne DW. Computational methods for prodrug or drug analogue selection optimized for percutaneous delivery. In: Osborne DW, Amann AH, eds. Topical Drug Delivery Formulations. New York, NY: Marcel Dekker, 1990:109-125.
26. Foroutan SM, Watson DG. Synthesis and characterization of polyethylene glycol conjugates of hydrocortisone as potential prodrugs for ocular steroid delivery. Int J Pharm. 1997;157:103-111.
27. Ricci M, Puglia C, Bonina F, Di Giovanni C, Giovagnoli S, Rossi C. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): in vitro and in vivo studies. J Pharm Sci. 2005;94:1149-1159.
28. Davaran S, Rashidi MR, Hashemi M. Synthesis and hydrolytic behavior of 2-mercaptoethyl ibuprofenate-polyethylene glycol conjugate as a novel transdermal prodrug. J Pharm Pharmacol. 2003;55:513-517.
29. Lien EJ, Gao H. QSAR analysis of skin permeability of various drugs in man as compared to in vivo and in vitro studies in rodents. Pharm Res. 1995;12:583-587.
30. Bonina FP, Rimoli MG, Avallone L, et al. New oligoethylene ester derivatives of 5-iodo-2′-deoxyuridine as dermal prodrugs: synthesis, physicochemical properties, and skin permeation studies. J Pharm Sci. 2002;91:171-179.
31. Castelli F, Puglia C, Sarpietro MG, Rizza L, Bonina F. Characterization of indomethacin loaded lipid nanoparticles by differential scanning calorimetry. Int J Pharm. 2005;304:231-238.
32. Puglia C, Bonina F, Trapani G, Franco M, Ricci M. Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations. Int J Pharm. 2001;228:79-87.
33. Röpke CD, Kaneko TM, Rodrigues RM, et al. Evaluation of percutaneous absorption of 4-nerolidylcathecol from 4 topical formulations. Int J Pharm. 2002;249:109-116.